Summit Therapeutics (NASDAQ:SMMT) Coverage Initiated by Analysts at The Goldman Sachs Group
Equities researchers at The Goldman Sachs Group initiated coverage on shares of Summit Therapeutics (NASDAQ:SMMT – Get Free Report) in a report released on Friday, Marketbeat.com reports. The brokerage set a “buy” rating and a $42.00 price target on the stock. The Goldman Sachs Group’s price target would suggest a potential upside of 103.00% from […]
Equities researchers at The Goldman Sachs Group initiated coverage on shares of Summit Therapeutics (NASDAQ:SMMT – Get Free Report) in a report released on Friday, Marketbeat.com reports. The brokerage set a “buy” rating and a $42.00 price target on the stock. The Goldman Sachs Group’s price target would suggest a potential upside of 103.00% from […]
